Rallybio (RLYB) Total Liabilities (2020 - 2026)
Rallybio (RLYB) posted Total Liabilities of $4.2 million for Q1 2026, down 2.56% sequentially from $4.3 million in Q4 2025, and up 7.29% YoY from $3.9 million in Q1 2025.
Rallybio (RLYB) Total Liabilities (2020 - 2026) Analysis & Trends
Rallybio has reported Total Liabilities for 7 years, with the latest figure at $4.2 million in Q1 2026.
- Quarterly Total Liabilities rose 7.29% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 7.29% YoY) and the FY2025 annual result came in at $4.3 million, down 33.3% from the prior year.
- Total Liabilities eased to $4.2 million in Q1 2026 per RLYB's latest filing, from $4.3 million in the prior quarter.
- Over five years, Total Liabilities peaked at $12.4 million in Q2 2024 and troughed at $3.9 million in Q1 2025.
- A 5-year average of $7.7 million and a median of $7.8 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 68.89% in 2022, then tumbled 61.67% in 2025.
- Over 5 years, Total Liabilities stood at $11.1 million in 2022, then declined by 15.13% to $9.4 million in 2023, then tumbled by 31.6% to $6.5 million in 2024, then tumbled by 33.3% to $4.3 million in 2025, then retreated by 2.56% to $4.2 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $4.2 million, $4.3 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Rallybio | 95.20 Mn | 95.20 Mn | - | 3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.57 Mn |
| Mar 31, 2026 | 4.20 Mn |
| Dec 31, 2025 | 4.31 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | 5.04 Mn |
| Mar 31, 2025 | 3.91 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Sep 30, 2024 | 8.19 Mn |
| Jun 30, 2024 | 12.41 Mn |
| Mar 31, 2024 | 10.20 Mn |
| Dec 31, 2023 | 9.44 Mn |
| Sep 30, 2023 | 9.61 Mn |
| Jun 30, 2023 | 8.32 Mn |
| Mar 31, 2023 | 7.12 Mn |
| Dec 31, 2022 | 11.12 Mn |
| Sep 30, 2022 | 11.72 Mn |
| Jun 30, 2022 | 7.76 Mn |
| Mar 31, 2022 | 6.32 Mn |
| Dec 31, 2021 | 6.58 Mn |
| Sep 30, 2021 | 7.38 Mn |